#USA #Waltham #TRINITY #Verix #Tovana

Trinity Acquires Verix to Enhance TrinityEDGE with AI Capabilities

On October 20, 2026, Trinity, an industry leader in integrating human intelligence with artificial intelligence for life sciences, proudly announced its acquisition of Verix, a company renowned for its AI-powered commercial optimization solutions. This strategic move will incorporate Verix's patented Tovana™ platform into TrinityEDGE™, enhancing the operational efficiency and decision-making capabilities of commercial teams in the pharmaceutical sector.

Why This Acquisition Matters Now

The pharmaceutical industry has steadily adopted AI technologies but hasn't maximized their potential. According to Trinity's benchmarking survey of Commercial and Medical IT practices in 2025, nearly every organization reported some level of generative AI adoption, yet the confidence in innovation remained only at a modest average of 3 out of 5. Many organizations acknowledged feeling inadequately prepared to adapt swiftly to ongoing industry changes. Furthermore, only 10% of leaders within new product planning and commercial strategy expressed having a clearly scalable AI strategy.

This disconnect between acquiring AI technology and realizing its full potential is primarily attributed to the gap between insights and actionable steps. Insights can become outdated quickly, leading to ineffective targeting and planning. Traditional next-best-action tools are often underutilized due to a lack of trust in their recommendations. Companies frequently face the dilemma of investing in insights without translating them into impactful actions, costing them twice for insights and execution. The integration of Verix's Tovana™ with TrinityEDGE aims to bridge this insight-to-action gap effectively.

Expanding Trinity's Growth Footprint

This acquisition is also a pivotal point in Trinity's growth strategy. Over the last three years, Trinity has expanded its advisory and insights capabilities along with the TrinityEDGE platform, significantly increasing its operational scale through software, data integration, and AI technology, supported by 1,500 professionals worldwide. By incorporating Verix, Trinity deepens its relationships with key commercial functions like field sales and digital marketing, which extend beyond its traditional advisory roles.

Tovana is a well-established platform that has demonstrated its capabilities since 2007, being utilized in live deployments across various pharmaceutical and biotech companies. Its extensive experience in oncology and specialty markets has enabled significant increases in key performance indicators (KPIs) for commercial teams. For example, a major pharmaceutical division reported a 15-25% increase in new prescriptions following Tovana's implementation, showcasing the platform's potential for measurable commercial success.

Real-Time Value Delivery

A significant advantage of Tovana is its swift time to value, often realized in just weeks. It employs a pharmacy-specific data foundation, automated pipelines, and pre-built model toolkits, enabling clients to implement targeting and engagement strategies that have proven effective in real-world settings. This seamless integration is expected to revolutionize how pharmaceutical companies manage their commercial strategies.

What Clients Can Expect

As an outcome of this acquisition, clients will benefit from several enhanced capabilities:
1. Continuous Adaptation: Tovana's advanced targeting, segmentation, and omnichannel strategies allow for real-time adjustments based on market dynamics, ensuring that strategies remain relevant and effective throughout a quarter.
2. Actionable Recommendations: The insights generated will be explainable and grounded in extensive therapeutic knowledge, supplied directly into field workflows via FieldAdvisor, encouraging their operational usage.
3. Streamlined Partnerships: Existing clients of both Trinity and Verix will enjoy a more straightforward path from insights to execution, eliminating the need for additional vendors or extensive integrations.

In the months to come, Tovana's capabilities will be systematically integrated into the TrinityEDGE platform, with plans to launch initial joint offerings in the first half of 2027. Verix's CEO, Doron Aspitz, will join Trinity's leadership team, ensuring the continuity and development of the Tovana roadmap.

Leadership Insights

Scott Evangelista, the CEO of Trinity, emphasized, "Every commercial leader I meet seeks to effectively leverage AI to enhance interactions and strategic forecasting. Verix bridges the gap between insight and execution, allowing commercial teams to be proactive rather than reactive in their operations. This acquisition represents a significant advancement in our collective ability to integrate human and artificial intelligence in life sciences commercialization."

Doron Aspitz echoed this sentiment, stating, "Joining Trinity is a logical next step for Verix. Clients will retain the product they know while gaining additional context and support to enhance their competitive positioning in the market. Together, we can create a more seamless experience for clients, maximizing our combined offerings."

Conclusion

The acquisition of Verix marks an exciting development in the pharmaceutical industry's journey towards optimized commercial strategies driven by AI. With Trinity's commitment to transforming insight into actionable commercial success, both companies stand poised to lead the charge into a new era of life sciences commercialization, setting a benchmark for efficiency and effectiveness. As Tovana's capabilities become fully integrated into the TrinityEDGE platform, clients can anticipate robust improvements in their operational strategies and resulting market successes.